Cipla Ltd

in Rs. Cr.
Standalone Balance Sheet
Mar 22 Mar-21 Mar-20
12 mths 12 mths 12 mths
EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital 161.36 161.29 161.25
Total Share Capital 161.36 161.29 161.25
Reserves and Surplus 22,315.35 19,730.58 17,207.54
Total Reserves and Surplus 22,315.35 19,730.58 17,207.54
Employees Stock Options 36.84 35.69 34.17
Total Shareholders Funds 22,513.55 19,927.56 17,402.96
NON-CURRENT LIABILITIES
Deferred Tax Liabilities [Net] 55.96 104.91 112.97
Other Long Term Liabilities 72.06 143.36 165.3
Long Term Provisions 78.92 95.97 105.14
Total Non-Current Liabilities 206.94 344.24 383.41
CURRENT LIABILITIES
Short Term Borrowings 0 0 6.06
Trade Payables 1,378.93 1,495.49 1,612.12
Other Current Liabilities 718.84 575.89 459.61
Short Term Provisions 630.79 620.56 541.5
Total Current Liabilities 2,728.56 2,691.94 2,619.29
Total Capital And Liabilities 25,449.05 22,963.74 20,405.66
ASSETS
NON-CURRENT ASSETS
Tangible Assets 3,111.73 3,673.15 3,818.67
Intangible Assets 215.96 269.51 205.87
Capital Work-In-Progress 169.22 275.04 255.73
Intangible Assets Under Development 44.62 80.07 64
Other Assets 63.35 123.79 126.44
Fixed Assets 3,604.88 4,421.56 4,470.71
Non-Current Investments 8,934.88 7,720.99 6,355.32
Deferred Tax Assets [Net] 0 0 0
Long Term Loans And Advances 0 43.37 41.89
Other Non-Current Assets 884.66 585.64 510.68
Total Non-Current Assets 13,424.42 12,771.56 11,378.60
CURRENT ASSETS
Current Investments 2,038.80 2,004.84 834.43
Inventories 3,199.05 3,085.81 3,021.36
Trade Receivables 1,939.62 3,035.37 3,560.27
Cash And Cash Equivalents 1,428.03 874.8 523.07
Short Term Loans And Advances 0.89 1.9 4.49
OtherCurrentAssets 3,418.24 1,189.46 1,083.44
Total Current Assets 12,024.63 10,192.18 9,027.06
Total Assets 25,449.05 22,963.74 20,405.66
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities 975.31 1,972.95 3,121.80

Other Earnings 135.97 - 86.15

Standalone Profit & Loss account in Rs. Cr.

Mar-22 Mar-21 Mar-20
12 mths 12 mths 12 mths
INCOME
Revenue From Operations [Gross] 12,827.29 13,610.02 12,220.22
Less: Excise/Sevice Tax/Other Levies 0 0 0
Revenue From Operations [Net] 12,827.29 13,610.02 12,220.22
Other Operating Revenues 264.5 290.56 438.93
Total Operating Revenues 13,091.79 13,900.58 12,659.15
Other Income 666.7 230.28 892.85
Total Revenue 13,758.49 14,130.86 13,552.00
EXPENSES
Cost Of Materials Consumed 2,767.79 3,262.29 2,999.17
Purchase Of Stock-In Trade 2,850.85 1,847.85 1,363.12
Operating And Direct Expenses 0 0 0
Changes In Inventories Of FG,WIP And Stock-In
-528.4 -9.93 -43.08
Trade
Employee Benefit Expenses 1,729.16 2,038.88 1,911.08
Finance Costs 26.93 45.07 36.05
Depreciation And Amortisation Expenses 460.01 556.11 599.78
Other Expenses 2,905.92 3,039.93 3,721.57
10,212.26 10,780.20 10,587.69
Total Expenses
12 mths 12 mths 12 mths
Profit/Loss Before Exceptional, ExtraOrdinary
3,546.23 3,350.66 2,964.31
Items And Tax
Exceptional Items 0 0 0
Profit/Loss Before Tax 3,546.23 3,350.66 2,964.31
Tax Expenses-Continued Operations
Current Tax 887.24 904.38 545.96
Deferred Tax -30.4 -22 100.18
Total Tax Expenses 856.84 882.38 646.14
Profit/Loss After Tax And Before ExtraOrdinary
2,689.39 2,468.28 2,318.17
Items
Profit/Loss From Continuing Operations 2,689.39 2,468.28 2,318.17

Profit Loss From Discontinuing Operations 268.54 0 0

Net Profit Loss From Discontinuing Operations 268.54 0 0

Profit/Loss For The Period 2,957.93 2,468.28 2,318.17
Mar-22 Mar-21 Mar-20

12 mths 12 mths 12 mths

OTHER ADDITIONAL INFORMATION

EARNINGS PER SHARE
Basic EPS (Rs.) 36.67 30.61 28.76
Diluted EPS (Rs.) 36.63 30.57 28.72
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS
STORES, SPARES AND LOOSE TOOLS
DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend 403.35 0 564.26
Tax On Dividend 0 0 87.45
Equity Dividend Rate (%) 250 250 200
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS
Dividend Remittance In Foreign Currency - - -
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods 5,709.43 6,805.06 5,517.45
Other Earnings 135.97 - 86.15

20-UCO-632
Akshat S Luniya
Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company,
headquartered in Mumbai. Cipla primarily develops medicines to treat respiratory disease,
cardiovascular disease, arthritis, diabetes, depression, and many other medical conditions.

Cipla has 47 manufacturing locations across the world and sells its products in 86 countries.
It is the third largest drug producer in India.

History

In 1935, Cipla was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial &
Pharmaceutical Laboratories' in Mumbai. In July 1984, the name of the company was
changed to 'Cipla Limited'.

In 1985, the US FDA approved the company's bulk drug against HIV and other drugs to treat
poor people in the developing world. Led by the founder's son Yusuf Hamied, a Cambridge-
educated chemist, the company provided generic AIDS and other drugs to treat poor people
in the developing world. In 1995, Cipla launched Deferiprone, the world's first oral iron
chelator.[8] In 2001, Cipla offered antiretrovirals for HIV treatment at a fractional cost (less
than $350 per year per patient).

In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and
changed its name to Cipla Medpro South Africa Limited. At the time of the acquisition, Cipla-
Medpro had been a distribution partner for Cipla and was South Africa's third-biggest
pharmaceutical company. The company had been founded in 2002 and was known as
Enaleni Pharmaceuticals Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which
had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African
generics company,[15] and in 2008 it changed its name to Cipla-Medpro.

In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals,

two American pharmaceutical companies, for 555 million dollars.

In 2019 Cipla entered digital therapeutics by partnering with Wellthy Therapeutics in India
and Brandmed in South Africa.

Products and services

Cipla sells active pharmaceutical ingredients to other manufacturers as well as

pharmaceutical and personal care products, including escitalopram oxalate (anti-
depressant), lamivudine, and fluticasone propionate. They are the world's largest
manufacturer of antiretroviral drugs.
In July 2020, the company announced the introduction of Gilead Sciences' Remdesivir under
the brand name CIPREMI in India after reaching a voluntary licensing agreement with parent
company and DCGI approval for "restricted emergency use" in COVID-19 treatment of
critical confirmed patients.

Listings and Shareholding

The equity shares of Cipla are listed on the Bombay Stock Exchange,[27] where it is a
constituent of the BSE SENSEX index,[28] and the National Stock Exchange of India,[29]
where it is a constituent of the CNX Nifty.[30] Its Global Depository Receipts (GDRs) are
listed on the Luxembourg Stock Exchange.[26]

As of 30 September 2014, the promoter group, Y. K. Hamied and his family, held around
36.80% equity shares in Cipla. Around 148,000 individual shareholders held approx. 18.67%
of its shares.[31] LIC is the largest non-promoter shareholder with approx. 6.45%
shareholding in the company by the end of September 2013.[32]

Shareholders (as on 31-March-2014) Shareholding[31]

Promoter Group 36.80%

Foreign Institutional Investors (FII) 23.32%

Individual shareholders 19.00%

Insurance companies 10.30%

Private Corporate Bodies 04.68%

Mutual Funds and Unit Trust of India 04.43%

Non Resident Indians, Foreign Corporate Bodies and

03.46%
Others

Global Depository Receipts 01.10%

 Total 100.00 %

Board Of Directors

DIN Director Name Designation

02296740 UMANG VOHRA Managing Director

03412604 PUNITA LAL Director

06799942 PETER NDIMBIRWE MUGYENYI Director

00029084 MUSTAFA KHWAJA HAMIED Director

00027923 SAMINA HAMIED Wholetime Director

Awards and recognitions

 In 2012, Cipla received the Thomson Reuters India Innovation Award.

 Cipla won Dun & Bradstreet American Express Corporate Awards in 2006.
 In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian
companies.
 In 1980, Cipla won Chemexcil Award for Excellence for exports.
 In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list, in
a study conducted by BlueBytes, a leading Media Analytics firm in association with
TRA Research, a brand insights organization (both a part of the Comniscient Group).

20-UCO-632
Akshat S Luniya